Reduced L-Arginine and L-Arginine-ADMA-Ratio, and Increased SDMA after Norseman Xtreme Triathlon.

Christoffer Nyborg, Martin Bonnevie-Svendsen, Helene Støle Melsom, Jørgen Melau, Ingebjørg Seljeflot, Jonny Hisdal
Author Information
  1. Christoffer Nyborg: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway. ORCID
  2. Martin Bonnevie-Svendsen: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway.
  3. Helene Støle Melsom: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway.
  4. Jørgen Melau: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway. ORCID
  5. Ingebjørg Seljeflot: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway. ORCID
  6. Jonny Hisdal: Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway.

Abstract

Endothelial vasodilatory function is dependent on the NO synthesis from L-arginine by endothelial NO-synthetase (eNOS). eNOS can be inhibited by asymmetric dimethylarginine (ADMA) by competitive inhibition on the binding site, and symmetric dimethylarginine (SDMA) can reduce the L-arginine availability intracellularly through competing for transport over the cellular membrane. To study the NO synthesis after prolonged exercise, we assessed circulatory L-arginine, the L-arginine/ADMA ratio, and SDMA before, after, and on the day after the Norseman Xtreme triathlon, an Ironman distance triathlon. We found significantly reduced levels of L-arginine and the L-arginine/ADMA ratio and increased levels of SDMA after the race (all < 0.05). L-arginine rose toward baseline levels the day after the race, but ADMA increased beyond baseline levels, and SDMA remained above baseline the day after the race. The reduced levels of L-arginine and the L-arginine/ADMA ratio, and increased SDMA, after the race indicate a state of reduced capability of NO production. Increased levels of ADMA and SDMA, and reduced L-arginine/ADMA ratio, as seen the day after the race, are known risk markers of atherosclerosis and warrant further studies.

Keywords

References

  1. PLoS One. 2016 Nov 3;11(11):e0165811 [PMID: 27812151]
  2. Eur J Appl Physiol Occup Physiol. 1976 Dec 6;36(1):39-48 [PMID: 1001315]
  3. Int J Mol Sci. 2015 May 29;16(6):12230-42 [PMID: 26035753]
  4. Scand J Med Sci Sports. 2020 Jun;30(6):1008-1016 [PMID: 32153035]
  5. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10480-4 [PMID: 1720542]
  6. Biomed Pharmacother. 2002 Nov;56(9):439-45 [PMID: 12481980]
  7. Front Physiol. 2020 Jan 09;10:1550 [PMID: 31992987]
  8. Metabolites. 2020 Mar 01;10(3): [PMID: 32121570]
  9. Nitric Oxide. 1997 Feb;1(1):65-73 [PMID: 9701046]
  10. Eur J Appl Physiol. 2008 Oct;104(3):417-26 [PMID: 18548269]
  11. Clin Exp Pharmacol Physiol. 2011 Dec;38(12):796-803 [PMID: 21923750]
  12. Cell Mol Life Sci. 2021 Jul;78(13):5303-5324 [PMID: 34037806]
  13. Atherosclerosis. 2015 Mar;239(1):61-6 [PMID: 25576847]
  14. Front Biosci (Elite Ed). 2015 Jun 01;7:417-22 [PMID: 25961421]
  15. PLoS One. 2020 Sep 23;15(9):e0239158 [PMID: 32966338]
  16. Sports (Basel). 2021 Jun 17;9(6): [PMID: 34204566]
  17. J Am Soc Nephrol. 2006 Apr;17(4):1128-34 [PMID: 16481412]
  18. Br J Pharmacol. 2019 Jan;176(2):189-196 [PMID: 30341769]
  19. Int J Environ Res Public Health. 2019 Oct 28;16(21): [PMID: 31661892]
  20. Front Nutr. 2020 Aug 18;7:133 [PMID: 33015116]
  21. Amino Acids. 2001;20(1):13-23 [PMID: 11310927]
  22. BMJ Open Sport Exerc Med. 2019 Jan 21;5(1):e000486 [PMID: 30740234]
  23. J Am Coll Cardiol. 1994 Nov 15;24(6):1468-74 [PMID: 7930277]
  24. Mol Cell. 2009 Jan 16;33(1):1-13 [PMID: 19150423]
  25. Hypertension. 2014 Feb;63(2):376-82 [PMID: 24277765]
  26. Biochem J. 1976 Jan 15;154(1):179-84 [PMID: 1275907]
  27. Am J Physiol Cell Physiol. 2002 Jan;282(1):C134-43 [PMID: 11742806]
  28. J Appl Physiol (1985). 1996 Mar;80(3):1006-13 [PMID: 8964718]
  29. J Biomech. 2005 Oct;38(10):1949-71 [PMID: 16084198]
  30. Exp Physiol. 2003 Nov;88(6):699-710 [PMID: 14603368]
  31. Wien Klin Wochenschr. 2005 Dec;117(23-24):816-20 [PMID: 16437318]
  32. Nature. 1988 Jun 16;333(6174):664-6 [PMID: 3131684]
  33. PLoS One. 2017 Jun 13;12(6):e0179324 [PMID: 28609447]
  34. PLoS One. 2012;7(8):e43280 [PMID: 22900101]
  35. Eur J Pharmacol. 1988 Sep 13;154(2):213-6 [PMID: 3265919]
  36. Nitric Oxide. 2008 Dec;19(4):345-50 [PMID: 18799138]
  37. Lancet. 1992 Mar 7;339(8793):572-5 [PMID: 1347093]
  38. Free Radic Biol Med. 2002 Jan 15;32(2):122-31 [PMID: 11796200]
  39. J Mol Cell Cardiol. 2012 Sep;53(3):392-400 [PMID: 22705145]
  40. Hypertension. 1986 Jan;8(1):37-44 [PMID: 3080370]
  41. Nat Rev Drug Discov. 2002 Dec;1(12):939-50 [PMID: 12461516]
  42. Circulation. 2017 Jul 11;136(2):126-137 [PMID: 28465287]
  43. Nutrients. 2020 May 02;12(5): [PMID: 32370176]
  44. Eur Heart J. 2008 Aug;29(15):1903-10 [PMID: 18426850]
  45. J Pharmacol Sci. 2015 Oct;129(2):83-94 [PMID: 26499181]

Grants

  1. /Aker BioMarine Antarctic AS

Word Cloud

Created with Highcharts 10.0.0SDMAL-argininelevelsraceNOADMAL-arginine/ADMAratiodayreducedtriathlonincreasedbaselinesynthesiseNOScandimethylarginineNorsemanXtremeIncreasedEndothelialvasodilatoryfunctiondependentendothelialNO-synthetaseinhibitedasymmetriccompetitiveinhibitionbindingsitesymmetricreduceavailabilityintracellularlycompetingtransportcellularmembranestudyprolongedexerciseassessedcirculatoryIronmandistancefoundsignificantly<005rosetowardbeyondremainedindicatestatecapabilityproductionseenknownriskmarkersatherosclerosiswarrantstudiesReducedL-ArginineL-Arginine-ADMA-RatioTriathlonironman

Similar Articles

Cited By